Alpha Blockers and Vasodilating Beta Blockers - Influence on Factors Involved in the Pathogenesis of Vascular Disease in Patients with Hypertension
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Hypertension. Part A: Theory and Practice
- Vol. 11 (5-6) , 1075-1083
- https://doi.org/10.3109/10641968909035392
Abstract
Antihypertensive drugs that interact with adrenoceptors have certain advantages and disadvantages (on the treatment of hypertension). Alpha-1 antagonists such as prazosin have favorable effects on plasma lipids but may produce excessive postural falls in blood pressure, particularly following the initial dose. Recently developed alpha-1 antagonists (doxazosin, terazosin) have longer durations of action than prazosin, allowing less frequent administration. Beta blockers may be cardioprotective but in contrast to alpha-1 antagonists tend to have adverse effects on plasma lipids. Drugs with combined beta and alpha-1 blocking activity such as labetalol have favorable metabolic effects but postural hypotension remains a problem. Recently developed drugs with different alpha-1/beta blocking ratios that differ from labetalol may prove to be more popular clinically. Several beta blockers with vasodilator activity which is not due to alpha-1 blockade have also been developed. These drugs appear to have favorable metabolic effects similar to drugs with alpha-1 blocking activity, but do not cause postural hypotension.Keywords
This publication has 7 references indexed in Scilit:
- Primary Prevention With Metoprolol in Patients With HypertensionJAMA, 1988
- EFFECTS OF ANTIHYPERTENSIVE DRUGS ON CARDIOVASCULAR RISK FACTORSClinical and Experimental Pharmacology and Physiology, 1988
- Effects of celiprolol on serum lipids in systemic hypertensionThe American Journal of Cardiology, 1988
- Celiprolol—Review of airways studiesThe American Journal of Cardiology, 1988
- Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprololThe American Journal of Cardiology, 1988
- Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham StudyJAMA, 1986
- THE α‐ AND β‐ADRENOCEPTOR BLOCKING POTENCIES OF LABETALOL AND ITS INDIVIDUAL STEREOISOMERS IN ANAESTHETIZED DOGS AND IN ISOLATED TISSUESBritish Journal of Pharmacology, 1982